• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Inspire Medical Systems, Inc. Announces Appointment of Carlton Weatherby as Chief Strategy Officer

    7/24/23 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email

    MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of Carlton Weatherby as Chief Strategy Officer, effective July 24, 2023.

    "We are very excited to welcome Carlton to the Inspire team," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "Carlton's vast experience in leadership roles across medtech, as well as his strategic vision, will be very valuable to us as we continue to grow and scale as an organization."

    Mr. Weatherby joins Inspire from Medtronic where he most recently served as Vice President and General Manager of their Spine & Biologics Business since 2021. Prior to this role, Mr. Weatherby served as Vice President of Strategic Sales and held various roles in corporate development since joining Medtronic in 2011.

    Mr. Weatherby has over 15 years of experience in commercial and corporate strategy and business development leadership roles in the medical device industry. He received his Master in Business Administration from Harvard Business School in 2011 and his Bachelor of Arts in Human Biology from Stanford University in 2007.

    "I am thrilled to be joining Inspire at such an exciting inflection point in the company's maturation," said Mr. Weatherby. "I look forward to shaping the company's strategy in the years to come and contributing to Inspire's mission of serving the many patients with untreated OSA."

    About Inspire Medical Systems

    Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

    For additional information about Inspire, please visit www.inspiresleep.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, those regarding our expectations to commercialize Inspire therapy in France. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

    Investor and Media Contact

    Ezgi Yagci

    Vice President, Investor Relations

    [email protected]

    617-549-2443



    Primary Logo

    Get the next $INSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    11/20/2024$220.00 → $255.00Neutral → Buy
    BofA Securities
    5/8/2024$265.00 → $225.00Buy → Neutral
    BofA Securities
    4/19/2024$285.00Outperform
    RBC Capital Mkts
    3/19/2024$250.00Overweight
    Morgan Stanley
    2/6/2024$278.00Overweight
    KeyBanc Capital Markets
    1/19/2024$245.00Buy
    Jefferies
    1/2/2024$210.00Buy → Hold
    Stifel
    12/13/2023$245.00 → $187.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn exercised 4,000 shares at a strike of $16.00, increasing direct ownership by 17% to 28,046 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      6/6/25 6:06:02 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Officer Rondoni John sold $259,025 worth of shares (1,734 units at $149.38), decreasing direct ownership by 11% to 13,766 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/21/25 4:05:14 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Director Ellis Gary Lee was granted 1,266 shares, increasing direct ownership by 28% to 5,861 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/5/25 8:26:47 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inspire Medical Systems upgraded by BofA Securities with a new price target

      BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously

      11/20/24 7:43:58 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously

      5/8/24 7:48:44 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Inspire Medical Systems with a new price target

      RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00

      4/19/24 7:26:47 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      1/24/24 4:32:03 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    SEC Filings

    See more
    • Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

      6/13/25 6:19:04 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Inspire Medical Systems Inc.

      SD - Inspire Medical Systems, Inc. (0001609550) (Filer)

      5/30/25 4:12:28 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Inspire Medical Systems Inc.

      144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

      5/19/25 4:01:53 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 21, 2023 - FDA Roundup: March 21, 2023

      For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

      3/21/23 3:12:46 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inspire Medical Systems, Inc. to Present at the Truist Securities MedTech Conference

      MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspiresl

      6/3/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

      MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor

      5/30/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care